Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02158507
Title Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors University of Alabama at Birmingham, Scariot Foundation, GlaxoSmithKline, AbbVie

triple-receptor negative breast cancer


Lapatinib + Veliparib

Age Groups: adult
Covered Countries USA

No variant requirements are available.